Literature DB >> 18483273

Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.

Yaqing Wang1, Xiaojun Liu, Akira Matsuda, William Plunkett.   

Abstract

The cytosine nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-d-arabino-pentofuranosylcytosine (CNDAC) causes DNA single-strand breaks after its incorporation into DNA. This investigation sought to determine if DNA excision repair pathways were activated to repair this damage. Neither the base excision repair nor the mismatch repair pathway seemed to be involved. Cells deficient in the CSB protein, which initiates transcription-coupled nucleotide excision repair (NER) pathway (TC-NER), exhibited increased clonogenic sensitivity to CNDAC, whereas cells deficient in XPC, which initiates global genome NER, were slightly resistant relative to wild-type cells. The cells lacking either helicase XPB, which unwinds 5' of the lesion, or endonuclease XPF, which incises 5' to a lesion, exhibited increased clonogenic sensitivity to CNDAC, as did cells lacking the XPF partner protein ERCC1. This sensitization was independent of p53 function. Repletion of XPF restored sensitivity comparable with the wild type. In contrast, cells lacking either XPD, the 3'-helicase, or the 3'-endonuclease XPG were equally as sensitive as wild-type cells. In comparison, cells deficient in XPF were not sensitized to other cytosine nucleoside analogues, troxacitabine and cytarabine. Thus, the single-strand nick caused by CNDAC is recognized and, in part, repaired by the TC-NER pathway. NER proteins that function in the 5' direction relative to the UV-induced lesion also participate in the repair of the CNDAC-induced nick, in contrast to proteins that process on the 3' side of the lesion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483273     DOI: 10.1158/0008-5472.CAN-07-6885

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.

Authors:  Xiaojun Liu; Yaqing Wang; Sherri Benaissa; Akira Matsuda; Hagop Kantarjian; Zeev Estrov; William Plunkett
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

2.  Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.

Authors:  Xiaojun Liu; Yingjun Jiang; Billie Nowak; Sarah Hargis; William Plunkett
Journal:  Mol Cancer Ther       Date:  2016-07-29       Impact factor: 6.261

3.  Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Authors:  Xiaojun Liu; Yingjun Jiang; Billie Nowak; Bethany Qiang; Nancy Cheng; Yuling Chen; William Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-30       Impact factor: 3.333

Review 4.  Sapacitabine for cancer.

Authors:  Xiaojun Liu; Hagop Kantarjian; William Plunkett
Journal:  Expert Opin Investig Drugs       Date:  2012-02-14       Impact factor: 6.206

5.  Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Authors:  Hagop Kantarjian; Stefan Faderl; Guillermo Garcia-Manero; Selina Luger; Parameswaran Venugopal; Lori Maness; Meir Wetzler; Steven Coutre; Wendy Stock; David Claxton; Stuart L Goldberg; Martha Arellano; Stephen A Strickland; Karen Seiter; Gary Schiller; Elias Jabbour; Judy Chiao; William Plunkett
Journal:  Lancet Oncol       Date:  2012-10-15       Impact factor: 41.316

6.  Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

Authors:  Hagop Kantarjian; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Robert Westwood; Simon R Green; Judy H Chiao; Patricia A Boone; Jorge Cortes; William Plunkett
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

7.  Insight into mechanisms of 3'-5' exonuclease activity and removal of bulky 8,5'-cyclopurine adducts by apurinic/apyrimidinic endonucleases.

Authors:  Abdelghani Mazouzi; Armelle Vigouroux; Bulat Aikeshev; Philip J Brooks; Murat K Saparbaev; Solange Morera; Alexander A Ishchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

Review 8.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

9.  CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death.

Authors:  Xiaojun Liu; Yingjun Jiang; Kei-Ichi Takata; Billie Nowak; Chaomei Liu; Richard D Wood; Walter N Hittelman; William Plunkett
Journal:  Mol Cancer Ther       Date:  2019-09-09       Impact factor: 6.261

10.  Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.

Authors:  Sucheta Jagan; Laura A Paganessi; Robin R Frank; Parameswaran Venugopal; Melissa Larson; Kent W Christopherson
Journal:  Adv Hematol       Date:  2012-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.